DBVT DBV Technologies S.A.

9.79
-0.2  -2%
Previous Close 9.99
Open 9.63
Price To Book 11.38
Market Cap 1,066,949,601
Shares 108,983,616
Volume 836,704
Short Ratio
Av. Daily Volume 506,186
Stock charts supplied by TradingView

NewsSee all news

  1. DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020

    Montrouge, France, February 24, 2020 DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today

  2. DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children

    Montrouge, France, February 21, 2020 DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children DBV Technologies (GREY:DBVTF), a clinical-stage

  3. DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference

    Montrouge, France, February 10, 2020 DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced

  4. Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020

    Monthly information regarding the total number of voting rights and  total number of shares of the Company as of January 31, 2020 and February 4, 2020 (Article 223-16 of the General Regulations of the Autorité des

  5. DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer

    Montrouge, France, February 6, 2020 DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data released February 2018.
Viaskin Milk
Cow’s milk protein allergy (CMPA)
PDUFA date August 5, 2020. Advisory Committee meeting May 15, 2020.
Viaskin Peanut
Peanut allergy
Phase 3 (Part B) initiation announced October 26, 2018.
Viaskin Peanut (EPITOPE)
Peanut allergy

Latest News

  1. DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020

    Montrouge, France, February 24, 2020 DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today

  2. DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children

    Montrouge, France, February 21, 2020 DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children DBV Technologies (GREY:DBVTF), a clinical-stage

  3. DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference

    Montrouge, France, February 10, 2020 DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced

  4. Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020

    Monthly information regarding the total number of voting rights and  total number of shares of the Company as of January 31, 2020 and February 4, 2020 (Article 223-16 of the General Regulations of the Autorité des

  5. DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer

    Montrouge, France, February 6, 2020 DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today

  6. DBV Technologies Announces Closing of Global Offering

    Montrouge, France, February 4, 2020 DBV Technologies Announces Closing of Global Offering DBV Technologies (the "Company") (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced the settlement and

  7. DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

    Montrouge, France, January 30, 2020 DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the

  8. DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position

    Montrouge, France, January 29, 2020 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash

  9. Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

    AMF REGULATED INFORMATIONMontrouge, France, January 15, 2020 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today

  10. Monthly information regarding the total number of voting rights and total number of shares of the Company

         Monthly information regarding the total number of voting rights and  total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE

  11. DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy

    Montrouge, France, January 8, 2020 DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy Patients

  12. DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer

    Montrouge, France, January 2, 2020 DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced the

  13. Monthly information regarding the total number of voting rights and total number of shares of the Company

    Monthly information regarding the total number of voting rights and  total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext

  14. Monthly information regarding the total number of voting rights and total number of shares of the Company

          Monthly information regarding the total number of voting rights and  total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE

  15. DBV Technologies to Present at the Stifel 2019 Healthcare Conference

    Montrouge, France, November 5, 2019 DBV Technologies to Present at the Stifel 2019 Healthcare Conference DBV Technologies, (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that Kevin Trapp,

  16. DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019

    Montrouge, France, October 24, 2019 DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 New analysis evaluates quality of life in patients receiving

  17. DBV Technologies Announces Closing of Global Offering

    Montrouge, France, October 15, 2019 DBV Technologies Announces Closing of Global Offering DBV Technologies (the "Company") (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced the settlement and

  18. DBV Technologies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

    Montrouge, France, October 10, 2019 DBV Technologies Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American

  19. DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

    Montrouge, France, October 9, 2019 DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the

  20. DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position

    Montrouge, France, October 8, 2019 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash

  21. DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy

    Montrouge, France, October 4, 2019DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy If approved, Viaskin Peanut would be the first and only epicutaneous

  22. Monthly information regarding the total number of voting rights and total number of shares of the Company

                                                                                                                                                                                                                                

  23. Monthly information regarding the total number of voting rights and total number of shares of the Company